May I congratulate the authors and editors of the article about use of imaging in the detection of drug mules and body stuffers (February/March 2008, page 36). I found the article very interesting, and there is no doubt about the technical advances CT is making, in particular in problem-solving.
One issuethat of radiationhas, however, not been addressed sufficiently, in my opinion. A CT scan of the abdomen and pelvis carries a significant radiation exposure. The concerned patients will often be young and/or potentially need a repeat scan. These points should not be overlooked.
In the case of a medical emergency, the radiation dose is justified due to the potential adverse outcome if no direct action is taken. Indications of "screening for drugs" and "to aid legal prosecution," on the other hand, should be disputed.
Imagine the hypothetical case of a 19-year-old asymptomatic female traveler who is suspected of carrying drugs. Is it ethical to subject her to a CT scan of the abdomen/pelvis? What happens if she turns out to be in the early stages of pregnancy, which cannot always be excluded? What would happen if she were found to be innocent? Would she be within her rights to seek compensation? Could she sue the police if she were to develop bowel cancer 15 to 20 years later?
Such cases raise very important questions from ethical, medicolegal, and radiation protection points of view. As radiologists, we are gatekeepers of radiation use, and we should not forget this important role. Therefore, we may choose not to use CT to its full potential but seek alternatives with less risk attached, even if they are more tedious and the pictures not quite as "pretty." Ultrasound and MRI were mentioned in the article. Maybe they should be used first.
Dr. Christiane Nyhsen is a consultant radiologist, City Hospitals Sunderland, U.K., and chair, Radiology Trainees Forum. Dr. Nyhsen is also a member of DI Europe's Editorial Advisory Board.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.